Background: Multiple myeloma (MM) is a malignancy of clonal plasma cells accounting for
approximately 10% of haematological malignancies and 1.8% of all malignancies. Transgelin2 was found to be a marker of interstitial fibrosis, glomerulosclerosis, and renal damage. The
aim of this work was to evaluate the serum transgelin-2 as a predictor of renal impairment in
patient with multiple myeloma and to determine the effect of transgellin-2 of chronic kidney
disease patients with multiple myeloma.
Methods: This observational case control study was conducted on 52 participants with MM
with chronic kidney disease (CKD).
Patients were divided equally into two groups: Case group: included patients with MM with or
without CKD and control group: included only CKD patients. serum transgelin-2 levels were
assessed in all patients using suitable ELISA kits. |
